journal
MENU ▼
Read by QxMD icon Read
search

Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences

journal
https://read.qxmd.com/read/30742585/effect-of-the-fexofenadine-on-the-expression-of-hrh-1-and-hrh-4-receptor-in-peripheral-blood-mononuclear-cell-isolated-from-children-with-diagnosed-allergy-in-vitro-study-short-communication
#1
Natalia Kordulewska, Anna Cieślińska, Ewa Fiedorowicz, Beata Jarmołowska, Elżbieta Kostyra
PURPOSE: Fexofenadine (FXF) is the active metabolite of terfenadine with selective peripheral H1 receptor antagonist activity. FXF is a third-generation antihistamine, non-sedating, rapid and very long acting used in symptoms associated with allergic diseases such as allergic rhinitis, asthma and dermatitis. The pleiotropic effects of histamine are mediated by four types of receptors that belong to the G-protein-coupled receptor family: histamine H1 receptor (HRH-1), histamine H2 receptor, histamine H3 receptor, and histamine H4 receptor...
2019: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://read.qxmd.com/read/30730832/evaluation-of-the-impact-of-an-inpatient-hyperglycemia-protocol-on-glycemic-control
#2
Haley N Ilcewicz, Erin K Hennessey, Carmen B Smith
PURPOSE: Inpatient hyperglycemia is associated with poor outcomes. Existing research assessing inpatient hyperglycemia protocols has shown improvements in average blood glucose levels with inconsistent results regarding rates of hypoglycemia and hyperglycemia. The objective of this study was to evaluate the impact of an inpatient hyperglycemia protocol on glycemic control. METHODS: This retrospective cohort study at a large, community teaching hospital included adult patients in non-critical care units requiring insulin administration for glycemic control...
2019: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://read.qxmd.com/read/30678750/prediction-of-hepatic-clearance-of-stereoselective-metabolism-of-carvedilol-in-liver-microsomes-and-hepatocytes-of-sprague-dawley-and-cytochrome-p450-2d-deficient-dark-agouti-rats
#3
Masahiro Iwaki, Toshiro Niwa, Hiroyuki Tanaka, Atsushi Kawase, Hiroshi Komura
Hepatic clearance (CLh) of carvedilol (CAR), which is eliminated via stereoselective metabolism by the CYP2D subfamily of cytochromes P450 (CYPs), was predicted using liver microsomes and hepatocytes from Sprague-Dawley (SD) rats and CYP2D-deficient Dark Agouti (DA) rats to determine the usefulness of prediction method. Plasma concentrations of CAR following intravenous injection to DA rats were higher than those in SD rats. The volume of distribution at steady state and total clearance (CLtot) of S-CAR were approximately two times greater than those of R-CAR in both strains...
2019: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://read.qxmd.com/read/30660205/antidepressant-use-and-risk-of-venous-thromboembolism-a-systematic-review-and-meta-analysis
#4
Ying Wang, Zhikang Ye, Lihong Liu, Xiangli Cui
PURPOSE: Studies provided conflicting results on whether antidepressant use increased the risk of venous thromboembolism (VTE). Our aim was to examine the association between antidepressant use and the risk of VTE. METHODS: Pubmed, Embase, and the Cochrane Library were searched up to March 13, 2018. Case-control studies and cohort studies that examined the association between antidepressant use and the risk of VTE, deep vein thrombosis or pulmonary embolism were included...
2019: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://read.qxmd.com/read/30636671/novel-approaches-for-efficient-delivery-of-tyrosine-kinase-inhibitors
#5
Zahra Moradpour, Leila Barghi
Epidermal growth factor receptors (EGFRs) have potential to be considered as therapeutic target for cancer treatment especially in cancer patients with overexpression of EGFR. Cetuximab as a first monoclonal antibody and Imatinib as the first small molecule tyrosine kinase inhibitor (SMTKI) were approved by FDA in 1998 and 2001. About 28 SMTKIs have been approved until 2015 and a large number of compound with kinase inhibitory activity are at the different phases of clinical trials. Although Kinase inhibitors target specific intracellular pathways, their tissue or cellular distribution are not specific...
2019: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://read.qxmd.com/read/30636670/lifitegrast-ophthalmic-solution-5-0-for-treatment-of-dry-eye-disease-overview-of-clinical-trial-program
#6
Clara C Chan, C Lisa Prokopich
Dry eye disease (DED) is a common inflammatory disorder of the ocular surface. Millions of people are affected by DED worldwide. Lifitegrast is a novel drug designed to inhibit DED-associated ocular inflammation. Four clinical trials have shown that lifitegrast is well tolerated and effective in improving symptoms and signs of DED over 12 weeks. A fifth trial showed long-term safety over 1 year. Lifitegrast has been in clinical use for more than one year in the United States and was recently approved in Canada (in December 2017)...
2019: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://read.qxmd.com/read/30599819/a-review-of-beneficial-low-intensity-exercises-in-diabetic-peripheral-neuropathy-patients
#7
Carley E Johnson, Jody K Takemoto
The American Diabetic Association standards of medical care for diabetic patients recommends moderate intensity exercise to help manage diabetes; however, this recommendation may be unmanageable for patients who have become inactive or unable to reach this intensity. The purpose of this review is to determine if low-intensity exercises demonstrate improvement in diabetic peripheral neuropathy symptoms in order to utilize these exercises as a starting point for inactive patients. Studies in low-intensity exercises from 2013 to May 2018 were systematically searched in PubMed, SCOPUS, and Cochrane Library databases...
2019: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://read.qxmd.com/read/30599818/a-survey-of-the-regulatory-requirements-for-the-acceptance-of-foreign-comparator-products-by-participating-regulators-and-organizations-of-the-international-generic-drug-regulators-programme
#8
Alfredo Garcia Arieta, Craig Simon, Gustavo Mendes Lima Santos, Iván Omar Calderón Lojero, Zulema Rodríguez Martínez, Clare Rodrigues, Sang Aeh Park, Ji Myoung Kim, Ryosuke Kuribayashi, Yusuke Okada, Arno Nolting, Chantal Pfäffli, Wen-Yi Hung, Christopher Crane, April C Braddy, Joy Van Oudtshoorn, Diego Gutierrez Triana, Mitch Clarke
The acceptance of foreign comparator products is the most limiting factor for the development and regulatory assessment of generic medicines marketed globally. Bioequivalence studies have to be repeated with the local comparator products of each jurisdiction because it is unknown if the comparators of the different countries are the same product, with the consequent duplication of efforts by regulators and industry alike. The regulatory requirements on the acceptability of foreign comparator products of oral dosage forms differ between countries participating in the Bioequivalence Working Group for Generics of the International Pharmaceutical Regulators Programme...
2019: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://read.qxmd.com/read/30545445/appropriateness-of-ticagrelor-use-at-initiation-a-population-based-cohort-study
#9
Jean-Pierre Gregoire, Paul Poirier, Norma Pérez, Éric Demers, Jocelyne Moisan
PURPOSE: Ticagrelor is recommended following an acute coronary syndrome if used appropriately. Its use has not yet been well described in the context of ambulatory clinical practice. The objective of this study was to assess the proportion of ticagrelor new users who initiated this medication appropriately and explore associated factors. METHODS: A retrospective population-based inception cohort study was conducted using Quebec administrative databases. The study population included all Quebec residents aged ≥18 years who had a first ticagrelor prescription claim between 1 January, 2012, and 31 March, 2015, and had been continuously eligible in the Quebec public drug plan during the 365 days preceding the first ticagrelor claim...
2019: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://read.qxmd.com/read/30589641/pamam-dendrimer-enhanced-antibacterial-effect-of-vancomycin-hydrochloride-against-gram-negative-bacteria
#10
Azadeh Serri, Arash Mahboubi, Afshin Zarghi, Hamid Reza Moghimi
PURPOSE: The antibacterial activity of some antibiotics is specific to either Gram-positive or Gram-negative bacteria.  There are different mechanisms behind such insensitivities like inability of antibiotics to permeate through some bacterial membranes, as is the case for vancomycin in Gram-negative bacteria. The present investigation tries to overcome this problem by dendrimers, in order to make Gram-negative bacteria responsive to vancomycin. METHODS: The effects of generations 3 (G3) and 5 (G5) polyamidoamine amine-terminated dendrimers (NH2-PAMAM), on the antibacterial activity of vancomycin, were evaluated...
2018: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://read.qxmd.com/read/30522586/resveratrol-limits-lipogenesis-and-enhance-mitochondrial-activity-in-hepg2-cells
#11
Magdalena Izdebska, Mariola Herbet, Monika Gawrońska-Grzywacz, Iwona Piątkowska-Chmiel, Agnieszka Korga, Marcin Sysa, Magdalena Iwan, Dorota Natorska-Chomicka, Ewa Poleszak, Andrzej Wróbel, Sławomir Mandziuk, Jarosław Dudka
PURPOSE: The aim of this study was to evaluate the effect of resveratrol on de novo lipogenesis in HepG2 cells caused by high glucose concentrations. Increased lipogenesis in the liver is the main reason for the development of nonalcoholic fatty liver disease (NAFLD) - currently one of the most common chronic liver diseases. In developed countries, this disease is mostly associated with nutritional disorders, resulting from the increasing consumption of monosaccharides. Resveratrol is a natural polyphenol with a promising potential for NAFLD treatment...
2018: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://read.qxmd.com/read/30496036/the-use-of-high-sensitivity-c-reactive-protein-in-cardiovascular-disease-detection
#12
Ana Rita Castro, Sara Oliveira Silva, Sandra Clara Soares
Cardiovascular diseases (CVDs) are responsible for a high mortality rate worldwide. One of the most common causes of CVDs is vascular inflammation associated to atherosclerosis. Inflammatory biomarkers are used to assist the detection of CVDs and monitor their evaluation, prognosis and therapy implementation. C-reactive protein (CRP) is an acute phase protein produced after stimulation by pro-inflammatory cytokines. CRP is a biomarker of the inflammatory reaction and an important mediator of atherosclerosis...
2018: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://read.qxmd.com/read/30472978/development-characterization-and-pharmacokinetic-evaluation-of-a-crv431-loaded-self-microemulsifying-drug-delivery-system
#13
Daniel J Trepanier, Daren R Ure, Robert Thomas Foster
PURPOSE: The objective of this study was to develop a self-microemulsifying drug delivery system (SMEDDS) formulation for the oral delivery of CRV431, a non-immunosuppressive analogue of cyclosporine A. Relative to cyclosporine A, CRV431 is poorly soluble in lipid solvents and thusly presents a challenge for the development of a formulation of sufficient oral bioavailability for clinical use. METHODS: The solubility of CRV431, a cyclosporine derivative, was determined in a range of commonly used surfactants, oils and co-solvents...
2018: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://read.qxmd.com/read/30472977/non-alcoholic-steatohepatitis-nash-drug-discovery-building-a-consensus-on-adme-screening-tools-and-clinical-pharmacology-strategies-to-aid-candidate-development
#14
Ranjeet Prasad Dash, R Jayachandra Babu, Nuggehally R Srinivas
Number of drugs with different mechanisms of actions is undergoing clinical trials for non-alcoholic steatohepatitis (NASH). Given the complexity of the disease with respect to pathophysiology in the liver and associated changes in the renal function, it becomes apparent that a clear ADME (absorption, distribution, metabolism and excretion) strategy needs to be put in place for a successful nomination of a drug candidate for NASH. This review discusses using in vitro and in vivo ADME screens to understand the properties of drugs and to establish whether or not the chosen drug(s) can overcome the challenges related hepatic and renal transporters covering both uptake and efflux mechanisms imposed by NASH...
2018: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://read.qxmd.com/read/30465708/stat3-is-involved-in-il-6-mediated-downregulation-of-hepatic-transporters-in-mice
#15
Walaa Ali Abualsunun, Micheline Piquette-Miller
Interleukin (IL)-6 decreases hepatic expression of numerous transporters. Although IL-6 signaling occurs through STAT3, the extent of the involvement of the STAT3 signaling pathway has not been elucidated. PURPOSE: Our objective was to investigate whether IL-6-mediated effects occur through STAT3, and whether PXR plays a role in this regulation. METHOD: PXR null (-/-) or wild-type (+/+) male mice were pre-dosed with a selective STAT3 inhibitor S3I-201 (7.5 mg/kg ip) or vehicle (n=5-8/group) 30 minutes before receiving a single dose of IL-6 (1 µg ip) or saline...
2018: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://read.qxmd.com/read/30465707/progress-on-active-analgesic-components-and-mechanisms-of-commonly-used-traditional-chinese-medicines-a-comprehensive-review
#16
Ruizhou Wang, Lu Han, Qixia Gao, Dan Chen, Yun Wang, Xia Zhang, Xin Yu, Yueming Zhang, Zhiyong Li, Changcai Bai
Many clinical diseases are accompanied by the symptoms of pain, and the degree of pain is closely related to the patients' suffering. Therefore, effectively relieving pain has become one of the vital concerns of clinical treatment and analgesic drug research. Non-opioid drugs are mainly used for the clinical treatment of mild to moderate pain, whereas opioid drugs are mainly used for treating moderate to severe pain. However, opioid drugs easily elicit adverse reactions, such as gastrointestinal discomfort, addiction, dependence, and so on...
2018: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://read.qxmd.com/read/30458921/the-controversies-challenges-and-complexities-of-lyme-disease-a-narrative-review
#17
Marie Claire Van Hout
PURPOSE: Lyme disease has become an increasingly important global public health concern. METHOD: A narrative review was conducted and designed to present a broad perspective on Lyme disease, and describe its history and development in terms of clinical care and public health implications. A structured literature search was conducted based on the question; what is currently known about Lyme disease? RESULTS: The narrative review is presented in chronological order in terms of a summary of the history of Lyme disease, the complexities of clinical diagnosis, the problematic interpretation of serologic testing, the conflicting guidelines for diagnosis, treatment and management of chronic Lyme, and benefits of antibiotic treatment...
2018: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://read.qxmd.com/read/30424832/treating-children-with-asd-the-perspective-of-caregivers
#18
Noor Breik, I Fan Kuo, Shawn Bugden, Michael Moffat, Silvia Alessi-Severini
PURPOSE: Treatment of Autism Spectrum Disorders (ASD) is challenging. Parents/caregivers' perspective on the effectiveness of therapies and services available to their children is important but neglected in the literature on ASD.  This study investigated such perspective through questionnaire-guided interviews with a group of parents in the province of Manitoba (Canada). A secondary objective of the study was to explore how health care professionals and specifically pharmacists can assist in providing better care to children with ASD...
2018: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://read.qxmd.com/read/30407908/moving-towards-universal-coverage-of-direct-acting-antiviral-therapies-for-hepatitis-c-infection-in-canada-an-environmental-scan-of-canadian-provinces-and-international-jurisdictions
#19
Samantha Myers, Gurleen Khosa, I Fan Kuo, Donica Janzen, Silvia Alessi-Severini
BACKGROUND: Direct-acting antivirals (DAAs) have become the standard treatment for patients with chronic hepatitis C infections because of their high cure rates and favourable side effect profiles; however, access to this new class of agents has been limited because of its high cost.  Public payers across Canada have implemented strict criteria for drug coverage in order to contain expenditures. Efforts have been made to improve access to medication for this high-burden condition. Recent coverage criteria across national and international jurisdictions have been compared...
2018: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
https://read.qxmd.com/read/30407907/the-antioxidant-activity-of-recombinant-rat-hepatic-fatty-acid-binding-protein-t94a-variant
#20
Tyson Le, Yuewen Gong, Neal M Davies, Ryan Lillico, Ted Lakowski, Michael S Roberts, Frank J Burczynski
PURPOSE: Liver fatty acid binding protein (FABP1) is a cytoplasmic polypeptide that transports substrates throughout the cytosol and functions as an antioxidant. A common polymorphic variant, FABP1 T94A has a minor allele frequency of 26-38%, 8.3±1.9% homozygous in the human population. The purpose of this study was to mutate and isolate recombinant rat FABP1 to the T94A variant to evaluate the mutant's antioxidant activity using in vitro studies. METHODS: Site-directed mutagenesis was used to generate a mutation in rat cDNA within a pGEX-6p-2 vector...
2018: Journal of Pharmacy & Pharmaceutical Sciences: a Publication of the Canadian Society for Pharmaceutical Sciences
journal
journal
32989
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"